We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.
- Authors
Caggiari, Laura; Miolo, Gianmaria; Buonadonna, Angela; Basile, Debora; Santeufemia, Davide A.; Cossu, Antonio; Palmieri, Giuseppe; De Zorzi, Mariangela; Fornasarig, Mara; Alessandrini, Lara; Canzonieri, Vincenzo; Lo Re, Giovanni; Puglisi, Fabio; Steffan, Agostino; Cannizzaro, Renato; De Re, Valli
- Abstract
The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments.
- Subjects
STOMACH cancer; DISEASE susceptibility; CANCER invasiveness; CADHERINS; EPIDERMAL growth factor receptors; TRASTUZUMAB; GENETIC polymorphisms; THERAPEUTICS
- Publication
International Journal of Molecular Sciences, 2018, Vol 19, Issue 1, p47
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms19010047